Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

Frank C. Arnett, Steven M. Edworthy, D. Blöch et al. · Arthritis & Rheumatism · 1988 · 19.9K citations

Medicine, Clinical Sciences, Internal Medicine +12

Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Jonathan Edwards, L Szczepański, Jacek Szechiński et al. · New England Journal of Medicine · 2004 · 2.6K citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial

Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska et al. · Arthritis & Rheumatism · 2006 · 1.1K citations

Medicine, Internal Medicine, Pharmacotherapy +13

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

M. Schiff · Annals of the Rheumatic Diseases · 2006 · 393 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17